Prognostic Factors in Resected Biliary Tract Cancers and the Impact of Cytokeratin 20 Expression
Received Date : 12 May 2021
Accepted Date : 20 Aug 2021
Available Online : 03 Nov 2021
Doi: 10.37047/jos.2021-84414 - Article's Language: EN
J Oncol Sci. 2021;7(3):125-32
This is an open access article under the CC BY-NC-ND license
Objective: Surgical resection is the mainstay of treatment in biliary tract cancers. However, the prognostic factors after resection are not very well defined. Cytokeratins are a group of intermediate filaments present in epithelial tissues that play a crucial role in cell differentiation. Cytokeratin 20 (CK20) is frequently expressed in different types of cancers, but its effect on survival varies considerably. The current study aimed at assessing the prognostic factors as well as CK20 expression for survival outcomes, which has not yet been studied in this group of patients. Material and Methods: We performed a multicenter, retrospective analysis of patients diagnosed with biliary tract cancer and treated them with upfront surgery. In total, 81 patients from four oncology centers were involved in this study. We aimed to determine the impact of known clinicopathologic factors and CK20 expression on survival rates using Cox regression analysis. Results: Median follow-up was 21.6 months. Surgical margin status and lymph node metastases were independent factors for both disease-free (p=0.006 and p<0.001, respectively) and overall survival (OS) (p=0.004 and p<0.001, respectively), while perineural invasion (PNI) significantly influenced disease-free survival (DFS) (p=0.013). Patients with CK 20 expression had better DFS and OS; however, its prognostic effect was not demonstrated in multivariate analysis (p>0.05). Conclusion: Our study demonstrated that lymph node metastasis, positive surgical margins, and PNI were found to be potential prognostic factors for survival outcomes, whereas the CK20 expression was not precise enough to be considered as an independent factor affecting the prognosis.
  1. Aloia TA, Járufe N, Javle M, et al. Gallbladder cancer: expert consensus statement. HPB (Oxford). 2015;17(8):681-690. [Crossref]  [PubMed]  [PMC] 
  2. Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383(9935):2168-2179. [Crossref]  [PubMed]  [PMC] 
  3. Banales JM, Cardinale V, Carpino G, et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspec tives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016;13(5):261-280. [PubMed] 
  4. Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg. 1996; 224(4):463-473; discussion 473-475. [Crossref]  [PubMed]  [PMC] 
  5. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. [Crossref]  [PubMed] 
  6. Anderson C, Kim R. Adjuvant therapy for resected extrahepatic cholangiocarcinoma: a review of the literature and future directions. Cancer Treat Rev. 2009;35(4):322-327. [Crossref]  [PubMed] 
  7. DeOliveira ML, Cunningham SC, Cameron JL, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007;245(5):755-762. [Crossref]  [PubMed]  [PMC] 
  8. Lamarca A, Edeline J, McNamara MG, et al. Current standards and future perspectives in adjuvant treatment for biliary tract cancers. Cancer Treat Rev. 2020;84:101936. [Crossref]  [PubMed] 
  9. Herrmann H, Bär H, Kreplak L, Strelkov SV, Aebi U. Intermediate filaments: from cell architecture to nanomechanics. Nat Rev Mol Cell Biol. 2007;8(7):562-573. [Crossref]  [PubMed] 
  10. de Moura Castro Jacques C, de Aquino AM, Ramos-e-Silva M. Cytokeratins and dermatology. Skinmed. 2007;4(6):354-360. [Crossref]  [PubMed] 
  11. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 1982;31(1):11-24. [Crossref]  [PubMed] 
  12. Cabibi D, Licata A, Barresi E, Craxì A, Aragona F. Expression of cytokeratin 7 and 20 in pathological conditions of the bile tract. Pathol Res Pract. 2003;199(2):65-70. [Crossref]  [PubMed] 
  13. Saad RS, Cho P, Silverman JF, Liu Y. Usefulness of Cdx2 in separating mucinous bronchioloalveolar adenocarcinoma of the lung from metastatic mucinous colorectal adenocarcinoma. Am J Clin Pathol. 2004;122(3): 421-427. [Crossref]  [PubMed] 
  14. Matros E, Bailey G, Clancy T, et al. Cytokeratin 20 expression identifies a subtype of pancreatic adenocarcinoma with decreased overall survival. Cancer. 2006;106(3):693-702. [Crossref]  [PubMed] 
  15. Jiang J, Ulbright TM, Younger C, et al. Cytokeratin 7 and cytokeratin 20 in primary urinary bladder carcinoma and matched lymph node metastasis. Arch Pathol Lab Med. 2001; 125(7):921-923. [Crossref]  [PubMed] 
  16. Hernandez BY, Frierson HF, Moskaluk CA, et al. CK20 and CK7 protein expression in colorectal cancer: demonstration of the utility of a population-based tissue microarray. Hum Pathol. 2005;36(3):275-281. [Crossref]  [PubMed] 
  17. Schmitz-Winnenthal FH, Volk C, Helmke B, et al. Expression of cytokeratin-20 in pancreatic cancer: an indicator of poor outcome after R0 resection. Surgery. 2006;139(1):104-108. [Crossref]  [PubMed] 
  18. Yun SP, Seo HI. Prognostic impact of immunohistochemical expression of CK7 and CK20 in curatively resected ampulla of Vater cancer. BMC Gastroenterol. 2015;15:165. [Crossref]  [PubMed]  [PMC] 
  19. Luo HT, Liang CX, Luo RC, Gu WG. Identification of relevant prognostic values of cytokeratin 20 and cytokeratin 7 expressions in lung cancer. Biosci Rep. 2017;37(6): BSR201710 86. [Crossref]  [PubMed]  [PMC] 
  20. Ando H. Embryology of the biliary tract. Dig Surg. 2010;27(2):87-89. [Crossref]  [PubMed] 
  21. Primrose JN, Fox RP, Palmer DH, et al; BILCAP study group. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019; 20(5):663-673. Erratum in: Lancet Oncol. 2019. [PubMed] 
  22. Edeline J, Benabdelghani M, Bertaut A, et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol. 2019;37(8):658-667. [Crossref]  [PubMed] 
  23. Oven Ustaalioglu BB, Bilici A, Seker M, et al. Prognostic factors for operated gallbladder cancer. J Gastrointest Cancer. 2019;50(3): 451-457. [Crossref]  [PubMed] 
  24. Beetz O, Klein M, Schrem H, et al. Relevant prognostic factors influencing outcome of patients after surgical resection of distal cholangiocarcinoma. BMC Surg. 2018;18(1):56. [Crossref]  [PubMed]  [PMC] 
  25. Morini S, Perrone G, Borzomati D, et al. Carcinoma of the ampulla of Vater: morphological and immunophenotypical classification predicts overall survival. Pancreas. 2013;42(1): 60-66. [Crossref]  [PubMed] 
  26. Min YS, Yi EH, Lee JK, et al. CK20 expression enhances the invasiveness of tamoxifen-resistant MCF-7 cells. Anticancer Res. 2012; 32(4):1221-1228. [PubMed] 
  27. Howlader NNA, Krapcho M, Miller D, et al. SEER Cancer Statistics Review, 1975-2017. National Cancer Institute. Bethesda, MD: 2020. [Link] 
  28. Reddy SK, Marroquin CE, Kuo PC, Pappas TN, Clary BM. Extended hepatic resection for gallbladder cancer. Am J Surg. 2007;194(3): 355-361. [Crossref]  [PubMed] 
  29. Rassam F, Roos E, van Lienden KP, et al. Modern work-up and extended resection in perihilar cholangiocarcinoma: the AMC experience. Langenbecks Arch Surg. 2018;403(3): 289-307. [Crossref]  [PubMed]  [PMC] 
  30. Murakami Y, Uemura K, Sudo T, et al. Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma. Ann Surg Oncol. 2011;18(3):651-658. [Crossref]  [PubMed] 
  31. Balachandran P, Agarwal S, Krishnani N, et al. Predictors of long-term survival in patients with gallbladder cancer. J Gastrointest Surg. 2006; 10(6):848-854. [Crossref]  [PubMed] 
  32. Ishihara S, Horiguchi A, Miyakawa S, Endo I, Miyazaki M, Takada T. Biliary tract cancer registry in Japan from 2008 to 2013. J Hepatobiliary Pancreat Sci. 2016;23(3):149-157. [Crossref]  [PubMed] 
  33. Wang Y, Yang H, Shen C, Luo J. Cholangiocarcinoma: prognostic factors after surgical resection in China. Int J Clin Exp Med. 2015; 8(4):5506-5512. [PubMed]  [PMC] 
  34. Lee SG, Song GW, Hwang S, et al. Surgical treatment of hilar cholangiocarcinoma in the new era: the Asan experience. J Hepatobiliary Pancreat Sci. 2010;17(4):476-489. [Crossref]  [PubMed] 
  35. Hong EK, Kim KK, Lee JN, et al. Surgical outcome and prognostic factors in patients with gallbladder carcinoma. Korean J Hepatobiliary Pancreat Surg. 2014;18(4):129-137. [Crossref]  [PubMed]  [PMC] 
  36. Liebig C, Ayala G, Wilks JA, Berger DH, Albo D. Perineural invasion in cancer: a review of the literature. Cancer. 2009;115(15):3379-3391. [Crossref]  [PubMed] 
  37. Burdy G, Panis Y, Alves A, Nemeth J, Lavergne-Slove A, Valleur P. Identifying patients with T3-T4 node-negative colon cancer at high risk of recurrence. Dis Colon Rectum. 2001;44(11):1682-1688. [Crossref]  [PubMed] 
  38. Horn A, Dahl O, Morild I. Venous and neural invasion as predictors of recurrence in rectal adenocarcinoma. Dis Colon Rectum. 1991; 34(9):798-804. [Crossref]  [PubMed] 
  39. McCready DR, Chapman JA, Hanna WM, et al. Factors associated with local breast cancer recurrence after lumpectomy alone: postmenopausal patients. Ann Surg Oncol. 2000; 7(8):562-567. [Crossref]  [PubMed] 
  40. Valle J, Wasan H, Palmer DH, et al; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273-1281. [Crossref]  [PubMed]